Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 3
2013 4
2014 4
2015 1
2016 2
2017 3
2018 6
2019 8
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, van Leeuwen DG, Sadelain M, Park JH, Brentjens RJ. Geyer MB, et al. JCI Insight. 2019 Apr 2;5(9):e122627. doi: 10.1172/jci.insight.122627. JCI Insight. 2019. PMID: 30938714 Free PMC article.
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.
Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF, Geyer MB, Goldberg AD, Mead E, Santomasso BD, Landa J, Rimner A, Riviere I, Landgren O, Brentjens RJ. Smith EL, et al. Among authors: Geyer MB. Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21. Cancer Immunol Res. 2019. PMID: 31113804
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC, Pappacena JJ, Tallman MS, Park JH, Geyer MB. King AC, et al. Among authors: Geyer MB. Leuk Res. 2019 Apr;79:27-33. doi: 10.1016/j.leukres.2019.02.009. Epub 2019 Feb 23. Leuk Res. 2019. PMID: 30831480
BRAF in the cross-hairs.
Geyer MB, Abdel-Wahab O, Tallman MS. Geyer MB, et al. Expert Rev Hematol. 2019 Mar;12(3):183-193. doi: 10.1080/17474086.2019.1583553. Epub 2019 Feb 26. Expert Rev Hematol. 2019. PMID: 30782032 Free PMC article. Review.
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Halton E, Lamanna N, Rademaker J, Sadelain M, Brentjens RJ, Park JH. Geyer MB, et al. Mol Ther. 2018 Aug 1;26(8):1896-1905. doi: 10.1016/j.ymthe.2018.05.018. Epub 2018 Jun 15. Mol Ther. 2018. PMID: 29910179 Free PMC article. Clinical Trial.
The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.
Hochberg J, Zahler S, Geyer MB, Chen N, Krajewski J, Harrison L, Militano O, Ozkaynak MF, Cheerva AC, Talano J, Moore TB, Gillio AP, Walters MC, Baxter-Lowe LA, Hamby C, Cairo MS. Hochberg J, et al. Among authors: Geyer MB. Bone Marrow Transplant. 2019 Feb;54(2):226-235. doi: 10.1038/s41409-018-0247-9. Epub 2018 Jun 13. Bone Marrow Transplant. 2019. PMID: 29899571 Free article. Clinical Trial.
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.
Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, Kabel CC, Patel MA, McGovern EM, Patel A, Schulman J, Dunbar AJ, Epstein-Peterson ZD, Menghrajani KN, Getta BM, Cai SF, Geyer MB, Glass JL, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt SA, Klimek V, Tallman MS, Roshal M. Xiao W, et al. Among authors: Geyer MB. Haematologica. 2019 Jul;104(7):1378-1387. doi: 10.3324/haematol.2018.203018. Epub 2018 Dec 6. Haematologica. 2019. PMID: 30523054 Free PMC article.
27 results
Jump to page